|
|
|
| home > white papers > Sourcing Commercial Drugs for Clinical Trials: US vs. EU Understanding the Differences - Myoderm |
|
|
 WHITE PAPERS |
|
Myoderm
|
|
Sourcing Commercial Drugs for Clinical Trials: US vs. EU Understanding the Differences
|
|
Sourcing commercial drugs for clinical trials is a dynamic process. There are many factors to consider: single source or regional sourcing, strategy, price, supply availability, lead times, and documentation are just a few. In the past, there were fewer clinical trials that required commercial drug sourcing, so demand was not as high. Today, the demand for commercial drugs in clinical trials has greatly increased and, as a result, inventory is tighter, orders are monitored more closely by manufacturers, and lead times have increased. This report highlights the key differences in sourcing from the US and EU.
|
|
|
|
|
|
|
 |
News and Press Releases |
 |
3P Biopharmaceuticals initiates partnership with American Biotech Zhittya for Parkinson’s disease treatment
3P and Zhittya began their relationship at the beginning of 2019
with 3P being selected as the CDMO to transfer the process for scaling
up and performing cGMP manufacturing for clinical studies. After
successfully achieving transfer of the process, 3P anticipates
manufacturing of the first cGMP batch by the second quarter of 2020.
More info >> |
|
 |
White Papers |
 |
|
Running Better Trials Taking an Intelligent Monitoring Approach
Bioclinica
When it comes to implementing a risk-based monitoring program, it is not
just about reducing monitoring visits and doing less Source Document
Verification (SDV). It’s about bringing together your people, a solid
process, and the right technology to run a better trial.
Success
with risk-based monitoring requires the ability to make sense of the
thousands, if not millions, of data points captured by multiple
disparate sources in a clinical trial. With the sheer volume of data
generated on a daily basis comes complexity. How does one make sense of
it all? Information overload burdens even the most experienced study
teams who struggle to understand which data matters most and what it
means.
More info >> |
|
 |
Industry Events |
 |
ESMO Targeted Anticancer Therapies Congress 2020
2-4 March 2020, Paris, France
A unique and international mix of experts, researchers and decision
makers both from academia and industry across the globe, will convene
in Paris for a three-day Congress aiming at exchanging knowledge,
experience and research innovations in cancer.
TAT
2020 will focus, among others, on novel strategies in immuno-oncology,
personalised medicine and molecular tumour boards, preclinical studies
to identify effective combination therapies, use of microbiome, tumour
agnostic trials, ADC technology, oncolytics, multispecific biological
constructs and targeting cytokines.
Participating in TAT 2020 will offer you the possibility to take part in
interdisciplinary discussions inspiring new ideas and new
collaborations.
More info >> |
|
|
|
